← FDA DRUG APPROVALS

FDA ANDA · ANDA078791

DIVALPROEX SODIUM

Sponsor: IMPAX LABS

APPLICATION
ANDA078791
TYPE
ANDA
ORIGINAL APPROVAL
2009-05-06
LATEST ACTION
2020-01-21
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

DIVALPROEX SODIUMDiscontinued
DIVALPROEX SODIUM EQ 500MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL
DIVALPROEX SODIUMDiscontinued
DIVALPROEX SODIUM EQ 250MG VALPROIC ACID · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-01-21Labeling · Supplement 18 · standardAP
2020-01-21Labeling · Supplement 16 · standardAP
2020-01-21Labeling · Supplement 14 · standardAP
2020-01-21Labeling · Supplement 20 · standardAP
2020-01-21Labeling · Supplement 13 · standardAP
2016-02-16Labeling · Supplement 9 · standardAP
2009-08-04Labeling · Supplement 2AP
2009-08-04Supplement · Supplement 1AP
2009-05-06OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →